Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2019-01-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/268 |